Rabitec
Rabies vaccine (live, oral) for foxes and raccoon dogs
Table of contents
Overview
This is a summary of the European public assessment report (EPAR) for Rabitec. It explains how the Agency assessed this veterinary medicine to recommend its authorisation in the European Union (EU) and its conditions of use. It is not intended to provide practical advice on how to use Rabitec.
Authorisation details
Product details | |
---|---|
Name |
Rabitec
|
Agency product number |
EMEA/V/C/004387
|
Active substance |
attenuated live rabies vaccine virus, strain SPBN GASGAS
|
International non-proprietary name (INN) or common name |
Rabies vaccine (live, oral) for foxes and raccoon dogs
|
Species |
|
Anatomical therapeutic chemical veterinary (ATCvet) codes |
QI07BD
|
Publication details | |
---|---|
Marketing-authorisation holder |
CEVA Santé Animale
|
Revision |
3
|
Date of issue of marketing authorisation valid throughout the European Union |
01/12/2017
|
Contact address |
10 avenue de La Ballastière |
Product information
18/12/2020 Rabitec - EMEA/V/C/004387 - IAIN/0006/G
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
-
Immunologicals for canidae
-
Live viral vaccines
Therapeutic indication
For the active immunisation of foxes and raccoon dogs against rabies to prevent infection and mortality.